Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company weekly Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E17.19 EPS (ttm)3.46 Insider Own0.11% Shs Outstand2.37B Perf Week3.26%
Market Cap141.05B Forward P/E9.47 EPS next Y6.28 Insider Trans-1.11% Shs Float2.34B Perf Month5.48%
Income5.66B PEG1.23 EPS next Q0.89 Inst Own59.80% Short Float6.46% Perf Quarter23.22%
Sales24.17B P/S5.83 EPS this Y28.70% Inst Trans3.09% Short Ratio9.42 Perf Half Y27.23%
Book/sh10.81 P/B5.50 EPS next Y44.76% ROA12.40% Target Price64.70 Perf Year14.32%
Cash/sh13.72 P/C4.33 EPS next 5Y14.00% ROE35.90% 52W Range42.48 - 59.17 Perf YTD14.43%
Dividend1.64 P/FCF28.67 EPS past 5Y14.50% ROI25.40% 52W High0.52% Beta0.68
Dividend %2.76% Quick Ratio3.70 Sales past 5Y6.60% Gross Margin70.80% 52W Low40.02% ATR1.07
Employees23300 Current Ratio3.80 Sales Q/Q5.60% Oper. Margin35.00% RSI (14)70.39 Volatility1.66% 1.74%
OptionableYes Debt/Eq1.41 EPS Q/Q-29.50% Profit Margin23.40% Rel Volume0.84 Prev Close58.90
ShortableYes LT Debt/Eq1.38 EarningsOct 31 BMO Payout47.10% Avg Volume16.05M Price59.48
Recom2.10 SMA203.41% SMA508.80% SMA20020.98% Volume13,547,580 Change0.98%
Nov-22-19Resumed Morgan Stanley Equal-Weight $60
Oct-17-19Resumed BofA/Merrill Buy $60
Aug-14-19Upgrade Atlantic Equities Neutral → Overweight $63
May-28-19Initiated Goldman Buy
May-20-19Downgrade Argus Buy → Hold
May-03-19Upgrade Barclays Equal Weight → Overweight $53 → $55
May-03-19Resumed JP Morgan Overweight $62
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Dec-05-19 07:50PM  UPDATE 2-FDA probes diabetes drug metformin for carcinogen NDMA Reuters
04:52PM  Bristol-Myers Squibb raises dividend MarketWatch
04:16PM  Bristol-Myers Squibb Announces Dividend Increase Business Wire
12:45PM  3 Reasons Why Growth Investors Shouldn't Overlook Bristol-Myers (BMY) Zacks
09:58AM  Bristol-Myers' Orencia Gets Breakthrough Therapy Tag for GvHD Zacks
09:37AM  4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal Zacks
09:10AM  Want To Retire Early? Learn the Intelligent Investing Secret - December 05, 2019 Zacks
Dec-04-19 05:52PM  Bayer and Teva Double Down on Worst M&A Deals of Decade GuruFocus.com
11:50AM  Is Bristol-Myers Squibb (BMY) a Great Value Stock Right Now? Zacks
10:08AM  Bristol-Myers' Reblozyl to be Reviewed by FDA Committee Zacks
09:22AM  Roche's Tecentriq-Chemo Combo Gets FDA Nod in First-Line NSCLC Zacks
09:11AM  5 High-Flying Stocks Near 52-Week High With More Room to Run Zacks
09:00AM  Pfizer Stock Is A Top Pharma Company But Should You Buy It? Investor's Business Daily
08:00AM  Bristol-Myers Has Now Acquired Celgene So, Should You Buy BMY Stock? Investor's Business Daily
07:02AM  Calculating The Intrinsic Value Of Bristol-Myers Squibb Company (NYSE:BMY) Simply Wall St.
06:59AM  Bristol-Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for ORENCIA® (abatacept) to Help Prevent Acute Graft-Versus-Host Disease, a Potentially Life-Threatening Complication After Stem Cell Transplant Business Wire
03:55AM  Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer (Revised) Zacks
Dec-03-19 08:17AM  Large-Cap Pharmaceuticals Industry Prospects Bright for 2020 Zacks
08:01AM  Top Ranked Income Stocks to Buy for December 3rd Zacks
07:38AM  Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes Business Wire
Dec-02-19 05:45PM  Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know Zacks
03:39PM  4 Top Stock Trades for Tuesday: ROKU, GOGO, BAC, BMY InvestorPlace
11:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
08:30AM  AstraZeneca's (AZN) Imfinzi Gets FDA Priority Tag for SCLC Zacks
06:33AM  Novartis-linked biotech firm raises $56M for new spinouts American City Business Journals
Nov-30-19 07:01PM  Is Bristol Myers Squibb Company (BMY) A Good Stock To Buy? Insider Monkey
Nov-29-19 01:42PM  Dont Write Off Energy Stocks Yet Barrons.com
Nov-28-19 09:45AM  Here is the 24th Most Popular Stock Among 752 Hedge Funds Insider Monkey
09:08AM  The Extreme Risks of Trading Your Own Retirement Assets - November 28, 2019 Zacks
Nov-27-19 02:46PM  Bristol-Myers Squibb Meets 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
09:24AM  Powerful Proof Anyone Can Invest for an Early Retirement - November 27, 2019 Zacks
07:32AM  Top Ranked Income Stocks to Buy for November 27th Zacks
07:10AM  Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer Zacks
Nov-26-19 06:59AM  Bristol-Myers Squibb to Hold Investor Webcast to Discuss ASH Highlights TEST Business Wire Releases
06:59AM  Bristol-Myers Squibb to Hold Investor Webcast to Discuss ASH Highlights Business Wire
06:07AM  4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal Zacks
03:09AM  Bristol-Myers Squibb Charts Prescribe Optimism in the Months Ahead TheStreet.com
Nov-25-19 01:04PM  Bristol-Myers Play on 3 Drugs Is a Good Bet, Analyst Says Barrons.com
Nov-23-19 03:41PM  Pfizer Is the Dows Worst Stock. A New Strategy Makes It Worth Another Look. Barrons.com
Nov-22-19 11:31AM  Pharma Stock Roundup: FDA Nod to NVS' & AZN's Drugs, BMY-CELG Merger Closes Zacks
09:43AM  Amgen (AMGN) Completes Otezla Buyout, Raises 2019 Guidance Zacks
09:27AM  Catching Up With Bristol-Myers Stock After Celgene Acquisition Barrons.com
09:00AM  Bristol-Myers Has Now Acquired Celgene So, Should You Buy BMY Stock? Investor's Business Daily
03:01AM  Seattle has potential as a biotech hub, but more companies must stay here and grow American City Business Journals
Nov-21-19 05:58PM  Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal Zacks
05:20PM  Bristol-Myers Binary Bet on Celgene Drugs Makes a Splash in Debut Barrons.com
04:28PM  Amgen Wraps Otezla Takeover And Other Fallout From BMY's Celgene Buy Investor's Business Daily
10:09AM  Bristol-Myers Stock Is Rising After Celgene Buy Closes Barrons.com
07:22AM  The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon Benzinga
06:59AM  Bristol-Myers Squibb Company Announces Final Results of Exchange Offers for Celgene Corporation Notes Business Wire
06:21AM  Amgen Completes Acquisition Of Otezla® (apremilast) PR Newswire
04:37AM  Bristol-Myers Closes $74 Billion Celgene Takeover; Shares Gain TheStreet.com
Nov-20-19 04:45PM  An All-or-Nothing Bet on 3 Drugs in Celgenes Pipeline Barrons.com
04:36PM  Bristol-Myers Squibb completes $74 billion acquisition of Celgene MarketWatch
04:33PM  At Long Last, Bristol-Myers Buys Celgene Barrons.com
04:20PM  Stocks close lower on report trade deal may not be completed this year MarketWatch
04:16PM  Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company Business Wire
10:23AM  Zacks.com featured highlights include: Bristol-Myers Squibb, Urban Outfitters, Hewlett Packard, Cardinal Health and British American Tobacco Zacks
09:32AM  Bristol-Myers Squibb Has a Skin Cancer Trial Setback TheStreet.com
09:07AM  Signs That Your Trading Will Ruin Your Retirement - November 20, 2019 Zacks
07:36AM  UPDATE 1-Bristol-Myers misses main goal of late-stage skin cancer trial Reuters
07:14AM  Bristol-Myers misses main goal of late-stage skin cancer trial Reuters
07:08AM  Bristol-Myers stock slides premarket after melanoma trial fails to meet main goal MarketWatch
06:58AM  Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected High-Risk Melanoma and PD-L1 <1% Business Wire
05:05AM  [video]Bristol-Myers Squibb Slips on Poor Skin Cancer Trial Results TheStreet.com
03:31AM  Stocks - Target, Lowes Rise Premarket; Urban Outfitters Falls Investing.com
Nov-19-19 11:16AM  Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500 PR Newswire
10:30AM  Hipster Antitrust Might End the Megamerger Party Bloomberg
10:14AM  4 Big Biotech Stocks Worth Considering Post Q3 Earnings Zacks
10:02AM  5 Excellent GARP Stocks With Discounted PEG Zacks
09:23AM  Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies Zacks
09:10AM  Powerful Proof Anyone Can Invest for an Early Retirement - November 19, 2019 Zacks
08:45AM  3 Reasons Growth Investors Will Love Bristol-Myers (BMY) Zacks
Nov-18-19 05:58PM  ServiceNow stock up 4% on news it is joining the S&P 500 MarketWatch
02:43PM  Edited Transcript of BMY earnings conference call or presentation 31-Oct-19 12:30pm GMT Thomson Reuters StreetEvents
09:36AM  Novartis Receives FDA Nod for Adakveo in Sickle Cell Disease Zacks
09:18AM  Bristol-Myers Gets FTC Clearance for Celgene Acquisition Zacks
09:10AM  Should Value Investors Buy Bristol-Myers Squibb (BMY) Stock? Zacks
Nov-17-19 03:40PM  AbbVie's Humira on Pace to Become Biggest Seller by 2024 GuruFocus.com
Nov-15-19 06:39PM  Bristol-Myers Squibb Company Announces It Expects No Further Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes Business Wire
05:43PM  FTC makes Celgene's Otezla divestiture official condition for Bristol-Myers acquisition MarketWatch
05:28PM  Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday Investor's Business Daily
05:18PM  UPDATE 2-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug Reuters
05:00PM  Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug Reuters
04:55PM  Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition Business Wire
07:12AM  Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates Zacks
06:59AM  Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes Business Wire
06:41AM  4 Big Drugmakers to Bet on After a Great Earnings Season Zacks
05:00AM  Bristol-Myers Squibb- A Beaten-Up Buy MoneyShow
Nov-14-19 09:44AM  Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss Zacks
Nov-13-19 01:14PM  AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark Zacks
Nov-12-19 03:24PM  How KKR Could Pull Off a Walgreens Takeover Barrons.com
10:03AM  The Extreme Risks of Trading Your Own Retirement Assets - November 12, 2019 Zacks
07:59AM  Bristol-Myers' Opdivo/Yervoy sBLA for HCC Gets Priority Review Zacks
06:59AM  Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes Business Wire
Nov-11-19 04:25PM  Can This Biotech Improve On Bristol-Myers' Blockbuster Cancer Drug? Investor's Business Daily
04:23PM  Pfizer-Merck KGaA's Bavencio Fails in 2nd Gastric Cancer Study Zacks
09:28AM  4 Biotech Stocks That Could Keep Beating Wall Street Zacks
09:09AM  Want To Retire Early? Learn the Intelligent Investing Secret - November 11, 2019 Zacks
09:05AM  Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug Zacks
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; FameWave Ltd.; Novartis; and Presage Biosciences. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Eid JosephSVPHead Global Medical AffairsDec 01Option Exercise0.002,82504,995Dec 03 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyNov 05Sale56.5625,0001,414,00031,963Nov 06 04:54 PM
Elicker John ESVP, Public Affairs & IRNov 05Sale56.6615,000849,90074,471Nov 06 04:54 PM
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.0059206,417Oct 03 04:46 PM
Santiago Karen MurphyControllerSep 01Option Exercise0.0064103,707Sep 04 05:17 PM
BERTOLINI ROBERT JDirectorJul 31Buy44.7211,000491,92011,397Aug 01 05:06 PM
Samuels Theodore R. IIDirectorMay 16Buy47.295,000236,44027,000May 20 04:36 PM
Santiago Karen MurphyControllerMay 16Sale47.563,065145,7713,066May 20 04:37 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400373,239May 06 04:40 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0011,594025,816Apr 05 04:32 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0014,180092,626Mar 13 07:42 AM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0015,707014,501Mar 13 07:41 AM
Dubow AdamChief Compliance & Ethics OffiMar 10Option Exercise0.003,735018,240Mar 13 07:41 AM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00173,4190422,683Mar 13 07:40 AM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0062,2550411,547Mar 13 07:39 AM
Biondi PaulSVP, Head of Strategy & BDMar 10Option Exercise0.008,61907,860Mar 13 07:39 AM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0019,9250141,077Mar 13 07:38 AM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0026,568063,652Mar 13 07:37 AM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMar 10Option Exercise0.005,864021,343Mar 13 07:36 AM
Santiago Karen MurphyControllerMar 10Option Exercise0.003,82506,850Mar 13 07:37 AM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0045,1700558,854Mar 13 07:35 AM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,577081,508Mar 13 07:34 AM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise17.5152,884925,999392,690Mar 04 04:42 PM
LEUNG SANDRAEVP, General CounselFeb 28Option Exercise17.51169,8932,974,826634,478Mar 04 04:42 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerFeb 02Option Exercise0.004,46504,465Feb 05 04:53 PM